Big Ten Cancer Research Consortium Sample Inquiry Form - Big Ten Cancer Research Consortium

Big Ten CRC Administrative Headquarters is pleased to provide investigators with access to our banked samples. Requests will be considered for research to be conducted by investigators at Big Ten CRC member institutions.

Contact Brittnay Lowe (blowe@hoosiercancer.org or 317-634-5842, ext. 28) for more information.

Complete the form below to request samples from our inventory. All requests will be evaluated according to the Big Ten CRC’s sample usage policies.

ESOPHAGEAL CANCER

Indication	Fresh Frozen Tissue	Paraffin Block	PBMC	Plasma	Serum	Unstained Slide	Urine	Whole Blood	Grand Total
BTCRC-ESO14-012	0	0	0	204	204	634	0	296	1338

KIDNEY CANCER

Indication	Fresh Frozen Tissue	Paraffin Block	PBMC	Plasma	Serum	Unstained Slide	Urine	Whole Blood	Grand Total
BTCRC-GU14-003	0	0	0	1659	1266	433	0	177	3535
BTCRC-GU16-043	0	15	0	168	166	353	0	230	932

LYMPHOMA

Indication	Fresh Frozen Tissue	Paraffin Block	PBMC	Plasma	Serum	Unstained Slide	Urine	Whole Blood	Grand Total
BTCRC-HEM15-028	21	1	64	147	39	163	0	106	541

ENDOMETRIAL ADENOCARCINOMA

Indication	Fresh Frozen Tissue	Paraffin Block	PBMC	Plasma	Serum	Unstained Slide	Urine	Whole Blood	Grand Total
BTCRC-GYN15-013	0	2	0	249	245	624	0	146	1266

ACUTE MYELOID LEUKEMIA (AML)

Indication	Fresh Frozen Tissue	Paraffin Block	PBMC	Plasma	Serum	Unstained Slide	Urine	Whole Blood	Grand Total
BTCRC-HEM17-092	0	0	0	33	63	0	0	28	124

NON-SMALL CELL LUNG CANCER

Indication	Fresh Frozen Tissue	Paraffin Block	PBMC	Plasma	Serum	Unstained Slide	Urine	Whole Blood	Grand Total
BTCRC-LUN15-029	0	0	0	223	222	97	0	90	632

Investigator's Name*
First Last
Email*
Institution*
What analysis will the samples be used for?*
Briefly describe the scientific purpose of your research.*
Name of potential lab to be used for the study
Lab point of contact
First Last
Email
Disease Type and Study Number*
Select disease type and study number to see available samples.
BTCRC-BRE15-016: A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Samples Available:
- Tissue (Archival)
- Whole Blood (Baseline) [Qty: 146 aliquots]
- Plasma (Baseline) [Qty: 146 aliquots]
- Plasma (EOT) [Qty: 95 aliquots]
- Serum (Baseline) [Qty: 146 aliquots]
- Serum (EOT) [Qty: 96 aliquots]
Request Samples:
BTCRC-ESO14-012: A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer

Samples Available:
- Tissue (Archival)
- Whole Blood (Baseline) [Qty: 114 aliquots]
- Plasma (Baseline) [Qty: 114 aliquots]
- Plasma (EOT) [Qty: 90 aliquots]
- Serum (Baseline) [Qty: 114 aliquots]
- Serum (EOT) [Qty: 90 aliquots]
Request Samples:
BTCRC-GI13-002: An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Samples Available:
- Tissue (Archival)
Request Samples:
BTCRC-GI18-149: Phase II Study of the Combination of Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma

Samples Available:
- Tissue (Archival)
- Whole Blood (Baseline) [Qty: 12 aliquots]
- Plasma (Baseline) [Qty: 9 aliquots]
- Plasma (EOT) [Qty: 3 aliquots]
- Serum (Baseline) [Qty: 9 aliquots]
- Serum (C4D1) [Qty: 3 aliquots]
- Serum (EOT) [Qty: 3 aliquots]
Request Samples:
BTCRC-GU14-003: Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma

Samples Available:
- Tissue (Archival)
- Whole Blood (Baseline) [Qty: 180 aliquots]
- Plasma (Baseline) [Qty: 180 aliquots]
- Plasma (EOT) [Qty: 135 aliquots]
- Serum (Baseline) [Qty: 180 aliquots]
- Serum (EOT) [Qty: 135 aliquots]
Request Samples:
BTCRC-GU15-023: Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients with Urothelial Cancer (T2-4 N0-2 M0) of the Bladder

Samples Available:
- Tissue (Archival)
- Plasma (Baseline) [Qty: 78 aliquots]
- Plasma (EOT) [Qty: 51 aliquots]
- Serum (Baseline) [Qty: 78 aliquots]
- Serum (EOT) [Qty: 51 aliquots]
Request Samples:
BTCRC-GU16-051: Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients

Samples Available:
- Tissue (Archival)
- Whole Blood (Baseline) [Qty: 24 aliquots]
- Plasma (Baseline) [Qty: 18 aliquots]
- Plasma (EOT) [Qty: 15 aliquots]
- Serum (Baseline) [Qty: 18 aliquots]
- Serum (EOT) [Qty: 15 aliquots]
Request Samples:
BTCRC-GYN15-013: Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma

Samples Available:
- Tissue (Archival)
- Whole Blood (Baseline) [Qty: 135 aliquots]
- Plasma (Baseline) [Qty: 135 aliquots]
- Plasma (EOT) [Qty: 102 aliquots]
- Serum (Baseline) [Qty: 135 aliquots]
- Serum (EOT) [Qty: 98 aliquots]
Request Samples:
BTCRC-HEM15-028: Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)

Samples Available:
- Tissue (Archival)
- Whole Blood (Baseline) [Qty: 40 aliquots]
- Plasma (Baseline) [Qty: 30 aliquots]
- Plasma (C3D1) [Qty: 9 aliquots]
- Serum (Baseline) [Qty: 30 aliquots]
- Serum (C3D1) [Qty: 9 aliquots]
Request Samples:
BTCRC-HEM16-085: Phase II study of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma

Samples Available:
- Tissue (Baseline Bx)
- Whole Blood (Baseline) [Qty: 8 aliquots]
- Plasma (Baseline) from CPT [Qty: 30 aliquots]
- Plasma (C3D1) [Qty: 45 aliquots]
- Plasma (C5D1) [Qty: 45 aliquots]
- Plasma w/ imaging RA (C9D1) [Qty: 30 aliquots]
- Plasma w/ imaging RA (C13D1) [Qty: 30 aliquots]
- Plasma w/ imaging RA (C19D1) [Qty: 15 aliquots]
- Serum (Baseline) [Qty: 6 aliquots]
- Serum (C3D1) [Qty: 6 aliquots]
- Serum (C5D1) [Qty: 6 aliquots]
- Serum w/ imaging RA (C9D1) [Qty: 3 aliquots]
- Serum w/ imaging RA (C13D1) [Qty: 3 aliquots]
- Serum w/ imaging RA (C19D1) [Qty: 3 aliquots]
Request Samples:
BTCRC-LUN15-017: A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients with Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy

Samples Available:
- Tissue (Archival)
- Whole Blood (Baseline) [Qty: 94 aliquots]
- Plasma (Baseline) [Qty: 91 aliquots]
- Plasma (EOT) [Qty: 75 aliquots]
- Serum (Baseline) [Qty: 95 aliquots]
- Serum (EOT) [Qty: 75 aliquots]
Request Samples:
BTCRC-LUN15-029: A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor

Samples Available:
- Tissue (Archival)
- Whole Blood (Baseline) [Qty: 90 aliquots]
- Plasma (Baseline) [Qty: 92 aliquots]
- Plasma (EOT) [Qty: 66 aliquots]
- Serum (Baseline) [Qty: 90 aliquots]
- Serum (EOT) [Qty: 64 aliquots]
Request Samples:
BTCRC-LUN16-081: Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

Samples Available:
- Whole Blood (Baseline) [Qty: 362 aliquots]
- Serum (Baseline) [Qty: 185 aliquots]
- Serum (C2D1) [Qty: 156 aliquots]
- Serum (EOT) [Qty: 145 aliquots]
Request Samples:
BTCRC-LUN17-139: A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

Samples Available:
- Whole Blood (Baseline) [Qty: 85 aliquots]
- Plasma (Baseline) [Qty: 388 aliquots]
- Plasma (EOT) [Qty: 170 aliquots]
- Serum (Baseline) [Qty: 66 aliquots]
- Serum (EOT) [Qty: 27 aliquots]
Request Samples:
Tissue (Archival)
Enter quantity needed
Tissue (Baseline Bx)
Enter quantity needed
Whole Blood (Baseline)
Enter quantity needed (aliquots)
Plasma (Baseline)
Enter quantity needed (aliquots)
Plasma (Baseline) from CPT
Enter quantity needed (aliquots)
Plasma (C3D1)
Enter quantity needed (aliquots)
Plasma (C5D1)
Enter quantity needed (aliquots)
Plasma w/ Imaging RA (C9D1)
Enter quantity needed (aliquots)
Plasma w/ Imaging RA (C13D1)
Enter quantity needed (aliquots)
Plasma w/ Imaging RA (C19D1)
Enter quantity needed (aliquots)
Plasma (EOT)
Enter quantity needed (aliquots)
Serum (Baseline)
Enter quantity needed (aliquots)
Serum (C2D1)
Enter quantity needed (aliquots)
Serum (C3D1)
Enter quantity needed (aliquots)
Serum (C4D1)
Enter quantity needed (aliquots)
Serum (C5D1)
Enter quantity needed (aliquots)
Serum w/ Imaging RA (C9D1)
Enter quantity needed (aliquots)
Serum w/ Imaging RA (C13D1)
Enter quantity needed (aliquots)
Serum w/ Imaging RA (C19D1)
Enter quantity needed (aliquots)
Serum (EOT)
Enter quantity needed (aliquots)

Donate

OnCore Login

Sample Inquiry Form

Illinois

Indiana

Iowa

Maryland

Michigan

Michigan State

Minnesota

Nebraska

Northwestern

Ohio State

Penn State

Purdue

Rutgers

Wisconsin

UIC